Pre-Transplant Immunological Profile and Risk Factor Analysis of Post-Transplant Lymphoproliferative Disease Development: The Results of a Nested Matched Case-Control Study
- 1 January 1999
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 36 (1-2) , 109-121
- https://doi.org/10.3109/10428199909145954
Abstract
Development of post-transplant lymphoproliferative disease (PTLD) is a major complication of organ transplantation.While immune mechanisms seem to play a major role in the development of PTLD, how the immune system contributes to the process of PTLD development or its regression remains unknown. Between 1990–1994, 303 organ transplant recipients were enrolled into a prospective study designed to analyze risk factors for PTLD. Using a nested case-control design, 9 PTLD and 18 control patients were matched for age, EBV serological status at the time of transplantation, and, in most cases, for the type of transplanted organ. The immunologic profiles of both groups were compared prior to and following transplantation. Immune measures included absolute numbers of lymphocytes and of subsets of T. B and natural-killer (NK) cells as well as spontaneous NK-cell and in virro generated LAK-cell activities. A consistent trend for higher levels at baseline as well as following transplantation for almost all immune parameters was observed in patients who developed PTLD. A high absolute count of activated NK cells (CD56+DR+) at baseline was found to be a significant predictor of PTLD development. The immunologic profile of patients who developed PTLD was consistent with pre- as well as post-transplant chronic immunologic stimulation, and not immunosuppression. In the PTLD group, 3 patients had pre-transplant autoimmune hepatitis and one had primary biliary cirrhosis, which suggests that the underlying presence of certain autoimmune disorders in organ transplant recipients might predispose to PTLD development.Keywords
This publication has 13 references indexed in Scilit:
- THE IMPORTANCE OF THE EFFECT OF UNDERLYING DISEASE ON REJECTION OUTCOMES FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATIONTransplantation, 1996
- Epstein-Barr virus strategy in normal and neoplastic B cellsCell, 1994
- IMMUNOREGULATORY ABNORMALITIES IN PATIENTS WITH EPSTEIN-BARR VIRUS-ASSOCIATED B CELL LYMPHOPROLIFERATIVE DISORDERSTransplantation, 1994
- Incidence of non-hodgkin lymphoma in kidney and heart transplant recipientsThe Lancet, 1993
- Expression of Epstein–Barr Virus–Encoded Small RNA (by the EBER-1 Gene) in Liver Specimens from Transplant Recipients with Post-Transplantation Lymphoproliferative DiseaseNew England Journal of Medicine, 1992
- Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant RecipientsNew England Journal of Medicine, 1990
- Natural killer cytotoxicity in the diagnosis of immune dysfunction: Criteria for a reproducible assayJournal of Clinical Laboratory Analysis, 1990
- Multiple Imputation for Nonresponse in SurveysPublished by Wiley ,1987
- REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPYThe Lancet, 1984
- Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activityJournal of Clinical Immunology, 1981